Selective AT1 Receptor Antagonism Enhances Sympathetically Mediated Vasoconstriction in Man

Lyons, Declan; Jackson, Stephen; Swift, Cameron

doi:10.1038/sj.clpt.6100023

Cited by 3 publications

(1 citation statement)

References 37 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that the RAS can interact with the sympathetic nervous system in a stimulatory manner at several different levels of the neuronal network [13]. AngII is well known to facilitate the release of noradrenaline from sympathetic nerve terminals in many tissues including the heart, kidney and blood vessels [30][31][32]. In contrast, a previous study did not confirm the role of AngII in the increased noradrenaline release or reduced noradrenaline reuptake in a hypertensive population [33].…”

Section: Discussionmentioning

confidence: 94%

Circulating renin–angiotensin system and catecholamines in childhood: is there a role for birthweight?

et al. 2008

View full text Add to dashboard Cite

There have been only a few reports on the sympathoadrenal and renin-angiotensin systems in children of small gestational age. The purpose of the present study was to investigate plasma levels of ACE (angiotensin-converting enzyme) activity, angiotensin and catecholamines in 8- to 13-year-old children and to determine whether there are correlations between the components of these systems with both birthweight and BP (blood pressure) levels. This clinical study included 66 children (35 boys and 31 girls) in two groups: those born at term with an appropriate birthweight [AGA (appropriate-for-gestational age) group, n=31] and those born at term but with a small birthweight for gestational age [SGA (small-for-gestational age) group, n=35]. Concentrations of angiotensin, catecholamines and ACE activity were determined in plasma. Circulating noradrenaline levels were significantly elevated in SGA girls compared with AGA girls (P=0.036). In addition, angiotensin II and ACE activity were higher in SGA boys (P=0.024 and P=0.050 respectively). There was a significant association of the circulating levels of both angiotensin II and ACE activity with BP levels in our study population. Although the underlying mechanisms that link restricted fetal growth with later cardiovascular events are not fully understood, the findings in the present study support the link between low birthweight and overactivity of both sympathoadrenal and renin-angiotensin systems into later childhood.

show abstract

Section: Discussionmentioning

confidence: 94%

Circulating renin–angiotensin system and catecholamines in childhood: is there a role for birthweight?

et al. 2008

View full text Add to dashboard Cite

show abstract

Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: surmountable vs. insurmountable antagonist

Jeong

Chae³

et al. 2014

International Journal of Cardiology

View full text Add to dashboard Cite

Darunavir

McKeage

Perry

Keam

2009

Drugs

116

View full text Add to dashboard Cite

Boosted darunavir was generally well tolerated in patients with HIV-1 infection in clinical trials, with most events being mild to moderate in severity. At 48-week analyses, the most common adverse events associated with once- or twice-daily boosted darunavir in treatment-experienced or -naive patients were diarrhoea, nausea, headache, upper respiratory tract infection and nasopharyngitis. The most common boosted darunavir-related grade 2-4 laboratory abnormalities in treatment-experienced patients included increased triglycerides and increased total cholesterol. Overall, boosted darunavir was associated with less diarrhoea than CPIs or boosted lopinavir in treatment-experienced and -naive patients, and a lower incidence of grade 2-4 elevations in triglycerides and total cholesterol than boosted lopinavir in treatment-naive patients. Treatment discontinuation because of adverse events occurred in 3% of boosted darunavir recipients and 7% of boosted lopinavir recipients during 48 weeks of therapy in treatment-naive patients. PHARMACOECONOMIC CONSIDERATIONS: Healthcare costs in the UK and US were estimated to be lower with boosted darunavir than with investigator-selected CPIs in treatment-experienced patients with HIV-1 infection in two 1-year cost analyses conducted from the perspective of a healthcare provider and using predicted costs based on CD4+ cell counts and clinical data from the POWER studies. The higher acquisition cost of boosted darunavir compared with CPIs was more than offset by the better efficacy of darunavir. In modelled cost-effectiveness analyses, boosted darunavir was predicted to be cost effective compared with other boosted CPIs in heavily pretreated adults from a healthcare payer perspective in Europe and from a societal perspective in the US. In a further model of a subgroup of patients with at least one primary International AIDS Society-USA PI mutation, boosted darunavir was predicted to be cost effective compared with boosted lopinavir from a healthcare payer perspective in Europe. The incremental costs per quality-adjusted life-year gained were within commonly accepted thresholds in all cost-effectiveness analyses.

show abstract

Selective AT1 Receptor Antagonism Enhances Sympathetically Mediated Vasoconstriction in Man

Cited by 3 publications

References 37 publications

Circulating renin–angiotensin system and catecholamines in childhood: is there a role for birthweight?

Circulating renin–angiotensin system and catecholamines in childhood: is there a role for birthweight?

Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: surmountable vs. insurmountable antagonist

Darunavir

Contact Info

Product

Resources

About